graft versus host disease

The FDA approved Bristol Myers Squibb & Co's (NYSE: BMY) Orencia (abatacept) for the prevention of acute graft-versus-host disease (GVHD) in combination with certain immunosuppressants. Orencia combined with calcineurin inhibitor (CNI) and methotrexate (MTX) becomes the...

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax's axatilimab. Related Content: Syndax Pharma Receives FDA Orphan Drug...

The FDA has approved Incyte Corporation's (NASDAQ: INCY) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for adult and pediatric patients 12 years and older with GVHD after the failure of one or two lines of systemic therapy. The...

Cellect Biotechnology Ltd (NASDAQ: APOP) announced the first ApoGraft transplantation in a Leukemia patient in a clinical trial in the U.S.  ApoGraft is designed to prevent graft-versus-host disease (GVHD) following bone marrow transplantation. Following the closing of the...

Equillium is set to begin trading on the Nasdaq Global Market under the ticker symbol “EQ.” The Details Equillium will offer 4.6 million shares of common stock in a price range between $14 and $16 per share. The company intends to raise $70 million, according to the S-1 filing. At the...